Aminophylline inhibits the enzyme phosphodiesterase and enhances the influx of calcium ions. It is used to treat the following conditions:
- Symptoms of acute airway obstruction in patients with Asthma, emphysema, and chronic bronchitis in addition to bronchodilators and other agents like corticosteroids.
- Off-label use for the treatment of angina and hypotension brought on by dipyridamole or regadenoson during nuclear cardiac stress testing
Note: Theophylline should not be administered to patients with asthma or other chronic lung conditions like COPD, according to the 2007 National Heart, Lung, and Blood Institute asthma guidelines and the 2018 Global Initiative for Asthma guidelines (GINA). This is because of the drug's serious adverse reactions.
Aminophylline Dose in Adults
Note: Calculating aminophylline dose should be based on the ideal body weight. Theophylline and aminophylline doses are not equivalent. Theophylline dose is about 79% of the aminophylline dose.
Aminophylline Dose in acute symptomatic bronchoconstriction:
- Patients who have not taken theophylline or aminophylline in the past 24 hours should receive an intravenous loading dosage of 5.7 mg/kg of aminophylline. The following formula should be used to determine the loading dose in individuals who have used aminophylline during the previous 24 hours.:
- Aminophylline Loading dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V )
- Aminophylline Loading dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V )
Maintenance dose of intravenous aminophylline:
- The maintenance dose should target plasma theophylline levels of 10 mcg/mL.
- Adults 60 years of age or younger:
- 0.51 mg/kg/hour to a maximum dose of 1,139 mg/day or when the serum target levels are achieved.
- Adults older than 60 years of age
- 0.38 mg/kg/hour to a maximum dose of 507 mg/day or until target levels indicate the need for a larger dose.
- Patients with decompensated cardiac disease, cor pulmonale, sepsis with multiorgan failure, and shock:
- 0.25 mg/kg/hour to a maximum dose of 507 mg/day or unless serum levels indicate the need for a larger dose.
- 0.25 mg/kg/hour to a maximum dose of 507 mg/day or unless serum levels indicate the need for a larger dose.
Dosage adjustment based on serum theophylline concentrations:
- Serum levels of less than 9.9 mcg/mL:
- If tolerated, increase the infusion rate by 25 %.
- Serum levels of 10 to 14.9 mcg/mL:
- Continue the same dose if the patient is tolerating it.
- Serum levels of 15 to 19.9 mcg/mL:
- Reduce the dose by 10 % even if the patient is tolerating it to avoid adverse drug reactions.
- Serum levels of 20 to 24.9 mcg/mL:
- Reduce the infusion rate by 25% even if the patient is tolerating it.
- Serum levels of 25 to 30 mcg/mL:
- Stop aminophylline infusion for 24 hours and reduce the subsequent infusion rate by 25%.
- Serum aminophylline dose of more than 30 mcg/mL:
- Stop the infusion, treat the patient for aminophylline overdose, and reduce the subsequent infusion rate by 50%.
- Stop the infusion, treat the patient for aminophylline overdose, and reduce the subsequent infusion rate by 50%.
Angina and hypotension caused by dipyridamole or regadenoson during nuclear cardiac stress testing are reversed:
- Administered intravenously during a 30- to 60-minute period, 50 to 250 mg. If necessary, the dose may be given again. In the absence of intravenous aminophylline, caffeine or intravenous theophylline may be utilised as substitutes.
Aminophylline Dose in Childrens
Aminophylline Dose in acute symptomatic bronchoconstriction:
Infants, children, and adolescents:
- Patients who have not taken theophylline or aminophylline in the past 24 hours should receive an intravenous loading dosage of 5.7 mg/kg of aminophylline.
- The following formula should be used to determine the loading dose in individuals who have used aminophylline during the previous 24 hours.:
- Aminophylline Loading dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V )
- Aminophylline Loading dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V )
Maintenance dose of aminophylline:
- Infants 4 to 6 weeks of age:
- 1.9 mg/kg/dose every twice daily.
- Infants 6 to 52 weeks of age:
- Dose (mg/kg/hour) = [(0.008 X age in weeks) + 0.21] divided by 0.79
- Children 1 to less than 9 years of age:
- 1.01 mg/kg/hour
- Children 9 to less than 12 years of age:
- 0.89 mg/kg/hour
- Adolescents 12 to less than 16 years of age:
- 0.63 mg/kg/hour
- Adolescents 12 to less than 16 years of age and smoking cigarette or marijuana smokers:
- 0.89 mg/kg/hour
- Adolescents older than 16 years of age (non-smokers):
- 0.51 mg/kg/hour
- Decompensated cardiac disease, cor pulmonale, liver disease, sepsis with multiorgan failure, and shock:
- 0.25 mg/kg/hour to a maximum dose of 507 mg/day unless the serum concentrations indicate the need for a larger dose.
- 0.25 mg/kg/hour to a maximum dose of 507 mg/day unless the serum concentrations indicate the need for a larger dose.
Dosage adjustment based on serum theophylline concentrations:
- Serum levels of less than 9.9 mcg/mL:
- If tolerated, increase the infusion rate by 25 %.
- Serum levels of 10 to 14.9 mcg/mL:
- Continue the same dose if the patient is tolerating it.
- Serum levels of 15 to 19.9 mcg/mL:
- Reduce the dose by 10 % even if the patient is tolerating it to avoid adverse drug reactions.
- Serum levels of 20 to 24.9 mcg/mL:
- Reduce the infusion rate by 25% even if the patient is tolerating it.
- Serum levels of 25 to 30 mcg/mL:
- Stop aminophylline infusion for 12 hours (in patients aged less than 16 years), for 24 hours ( in patients aged more than 16 years ), and reduce the subsequent infusion rate by 25%.
- Serum aminophylline dose of more than 30 mcg/mL:
- Stop the infusion, treat the patient for aminophylline overdose, and reduce the subsequent infusion rate by 50%.
Pregnancy Risk Factor C
- Theophylline crosses into the placenta, and adverse drug reactions have been observed in animal studies.
- Theophylline monographs in pregnancy are important to consider.
Use of theophylline during breastfeeding
- AAP has designated theophylline compatible with breastfeeding.
- Theophylline is excreted in breastmilk so dose adjustments should be made according to the monograph.
Aminophylline Dose in kidney impairment:
- No dosage adjustment is necessary in renal disease.
Aminophylline dose in patients with liver disease:
- Unless serum concentrations indicate the need for a higher dose, an initial beginning dose of 0.25 mg/kg/hour up to a maximum dose of 507 mg/day should be used.
- Patients with liver illness should use aminophylline with caution, and serum concentrations should be regularly checked.
Side Effects of Aminophylline:
Adverse reactions at therapeutic serum levels:
- Central nervous system:
- Headache, irritability, insomnia, restlessness, and seizure.
- Dermatologic:
- Allergic skin reactions and exfoliative dermatitis
- Gastrointestinal:
- Diarrhea, nausea, and vomiting
- Genitourinary:
- Transient Diuresis
- Neuromuscular & skeletal:
- Tremor
Contraindications to Aminophylline:
- Allergy or hypersensitivity to theophylline, aminophylline, or any other formulation ingredient.
- individuals with a high risk of developing arrhythmias and coronary artery disease
- Active peptic ulcer disorder.
Precautions and warnings
- Because of possible skin reactions, it is important to avoid extravasation.
- Overdosing can lead to theophylline toxicities, which can be fatal.
- Patients with:
- Acute pulmonary edema
- heart failure,
- Cor pulmonale
- febrile state
- Liver disease
- hypothyroidism,
- Sepsis with multiorgan failure
- shock
- neonates,
- impaired renal function
- Patients who smoke marijuana or tobacco.
- Patients with:
- Patients with epilepsy may experience Seizures that are exacerbated by theophylline.
Aminophylline: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy). |
|
Abiraterone Acetate | High risk of Inhibitors causing an increase in serum CYP1A2 Substrates concentrations |
Adalimumab | May lower serum levels of Theophylline derivatives. |
Alcohol (Ethyl) | Aminophylline serum levels might rise. |
Allopurinol | Theophylline derivative serum concentrations might rise. |
Amifampridine | Amifampridine can have stronger neuroexcitatory or seizure-potentiating effects when combined with substances having lower seizure threshold potential. |
Antithyroid Drugs | Theophylline derivative serum concentrations might rise. |
AtoMOXetine | May intensify Sympathomimetics' hypertensive effects. Sympathomimetics' tachycardic effects may be exacerbated by apoMOXetine. |
Barbiturates | May reduce serum levels of derivatives of theophylline. |
Beta-Blockers (Beta1 selective) | Derivatives of theophylline could not have as much bronchodilating effect. When utilising any beta-blocker, be cautious of diminished theophylline efficacy. Beta-1 selective drugs may lose their selectivity at larger doses, although they are less likely to antagonise beta-phylline than nonselective drugs. |
Broccoli | High risk of Inducers causing a decrease in serum CYP1A2 Substrates concentrations |
BuPROPion | May increase the neuroexcitatory or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. |
Cannabinoid-Containing Products | Sympathomimetics may increase the tachycardic effects of Sympathomimetics. Cannabidiol is an exception. |
Cannabis | High risk of Inducers causing a decrease in serum CYP1A2 Substrates concentrations |
Moderate CYP1A2 Inducers | High risk of Inducers causing a decrease in serum CYP1A2 Substrates concentrations |
Moderate CYP1A2 Inhibitors | Might decrease metabolism of CYP1A2 substrates (High Risk with Inhibitors). |
Cyproterone | High risk of Inducers causing a decrease in serum CYP1A2 Substrates concentrations |
Deferasirox | High risk of Inhibitors causing an increase in serum CYP1A2 Substrates concentrations |
Disulfiram | May increase serum concentrations of Theophylline derivatives. |
Estrogen Derivatives | Theophylline derivative serum concentrations might rise. |
Febuxostat | Active metabolite concentrations in the serum may rise after using theophylline derivatives. There may be an increase in 1-methylxanthine concentrations, a metabolite with uncertain therapeutic significance. |
Fluconazole | Theophylline derivative serum concentrations might rise. |
Formoterol | Formoterol's toxic/adverse effects may be exacerbated by Theophylline derivatives. Hypokalemic effects of Formoterol may be enhanced by Theophylline derivatives. |
Guanethidine | May increase the arrhythmogenic effects of Sympathomimetics. The hypertensive effects of Sympathomimetics may be enhanced by Guanethidine. |
Indacaterol | Theophylline derivatives can increase the toxic/adverse effects of Indacaterol. Hypokalemia may be enhanced by Indacaterol's Theophylline derivatives. |
Interferons | May reduce the metabolism of Theophylline derivatives. |
Isoniazid | Theophylline derivative serum concentrations might rise. |
Isoproterenol | May reduce serum levels of derivatives of theophylline. |
Lithium | Theophylline derivatives can lower serum levels of Lithium. |
Methotrexate | May increase serum concentrations of Theophylline derivatives. |
Obeticholic Acid | High risk of Inhibitors causing an increase in serum CYP1A2 Substrates concentrations |
Olodaterol | Theophylline derivatives may intensify the toxic/unfavorable effects of olodaterol. Olodaterol's hypokalemic effects could be exacerbated by derivatives of theophylline. |
Pefloxacin | Theophylline derivative serum concentrations might rise. |
Peginterferon Alfa-2b | High risk of Inhibitors causing an increase in serum CYP1A2 Substrates concentrations |
Pentoxifylline | May increase serum concentrations of Theophylline derivatives. |
Propafenone | Theophylline derivative serum concentrations might rise. |
QuiNINE | Theophylline derivative serum concentrations might rise. |
Ritonavir | May reduce serum levels of derivatives of theophylline. |
Solriamfetol | Sympathomimetics may intensify Solriamfetol's hypertensive effects. |
Sulfinpyrazone | May lower serum levels of Theophylline derivatives. |
Sympathomimetics | Other Sympathomimetics' toxic/unfavorable effects might be amplified. |
Tedizolid | May intensify Sympathomimetics' hypertensive effects. Sympathomimetics' tachycardic effects may be exacerbated by tedizolid. |
Teriflunomide | High risk of Inducers causing a decrease in serum CYP1A2 Substrates concentrations |
Thiopental | Thiopental's therapeutic effects may be diminished by Thiopental's use of aminophylline. |
Thyroid Products | Theophylline derivatives' metabolism might be increased. |
Ticlopidine | Theophylline derivative serum concentrations might rise. |
Tobacco (Smoked). | May reduce serum levels of derivatives of theophylline. |
Zafirlukast | The serum concentration of Zafirlukast may be decreased by Theophylline derivatives. The serum concentration of Theophylline derivatives may be increased by Zafirlukast. |
Risk Factor D (Consider therapy modifications) |
|
Adenosine | The therapeutic effects of Adenosine may be diminished by Theophylline Derivatives. |
Benzodiazepines | The therapeutic benefits of benzodiazepines can be lessened by derivatives of theophylline. |
Beta-Blockers (Nonselective) | May lessen theophylline derivatives' bronchodilatory effects. |
CarBAMazepine | Could decrease serum concentrations of Theophylline derivatives. CarBAMazepine may be decreased by Theophylline derivatives. Management: If possible, look for alternatives. |
Cimetidine | Theophylline derivatives' metabolism might be slowed down. |
Topical Cocaine | Sympathomimetics may increase hypertensive effects. Management: If possible, consider other options to this combination. Concurrent use of this combination can cause significant elevations in blood pressure and heart rate. You should also be aware of any signs of myocardial injury. |
FluvoxaMINE | May reduce the metabolism of Theophylline derivatives. |
Fosphenytoin | Theophylline derivatives' serum levels could drop. Theophylline derivatives may lower fosphenytoin levels. Management: Whenever possible, consider alternatives. If both medications are being used, keep an eye out for higher concentrations or effects of theophylline or phenytoin if the other is started or the dose is increased, or decreased concentrations or effects if the other is stopped or the dose is decreased. |
Iohexol | Agents with Seizure Threshold Lowering Potential can increase the toxic/adverse effects of Iohexol. The risk of seizures could be elevated. Management: Stop using agents that lower the seizure threshold 48 hrs before you start intrathecal iohexol. To resume these agents, wait at least 24 hours following the procedure. Consider using prophylactic anticonvulsants in non-elective procedures. |
Iomeprol | Agents with Seizure Threshold Lowering Potential can increase the toxic/adverse effects of Iomeprol. The risk of seizures could be elevated. Management: Stop using agents that lower the seizure threshold 48 hrs before you start intrathecal iomeprol. To resume these agents, wait at least 24 hours following the procedure. Consider using prophylactic anticonvulsants in non-elective procedures. |
Iopamidol | Agents with Seizure Threshold Lowering Potential can increase the toxic/adverse effects of Iopamidol. The risk of seizures could be elevated. Management: Stop using agents that lower the seizure threshold 48 hrs before you start intrathecal iopamidol. To resume these agents, wait at least 24 hours following the procedure. Consider using prophylactic anticonvulsants in non-elective procedures. |
Linezolid | Sympathomimetics may increase hypertensive effects. Patients receiving linezolid should be reduced in initial doses and closely monitored for an increased pressor response. There are no recommendations for dose adjustments. |
Antibiotics with Macrolide | Theophylline derivatives' metabolism might be decreased. Fidaxomicin, Roxithromycin, Telithromycin, Azithromycin (Systemic), and Roxithromycin. |
Mexiletine | Theophylline derivatives' metabolism might be slowed down. |
Pancuronium | The toxic/unfavorable effects of pancuronium may be increased by derivatives of theophylline. Pancuronium's ability to suppress neuromuscular activity may be lessened by theophylline derivatives. Patients who are concurrently taking theophylline derivatives may need a dose adjustment of pancuronium to cause paralysis. Concurrent use may have negative effects, like cardiac issues. |
Phenytoin | Theophylline derivatives' serum levels could drop. Derivatives of theophylline can lower phenytoin levels in the blood. Management: Whenever possible, consider alternatives. If both medications are being used, keep an eye out for higher concentrations or effects of theophylline or phenytoin if the other is started or the dose is increased, or decreased concentrations or effects if the other is stopped or the dose is decreased. |
Quinolones | May result in a reduction in the metabolism of derivatives of theophylline. Theophylline derivatives such as ciprofloxacin, enoxacin, and others are of particular concern. The potential for each medicine to cause seizures may be increased by theophylline/quinolone therapy. LevoFLOXacin Systemic; Delafloxacin; Gemifloxacin; Moxifloxacin; and Lomefloxacin. Systemic. Acid nalidixic. Sparfloxacin. |
Regadenoson | Regadenoson's vasodilatory effects may be diminished by Aminophylline. |
Thiabendazole | May reduce the metabolism of Theophylline derivatives. |
Vemurafenib | High potential for serum CYP1A2 substrates to increase as a result of inhibitors. Management: If the therapeutic index of the CYP1A2 substrat is limited, look into other options. For medications left out of this book, other monographs on drug interactions are available. |
Zileuton | Increased serum Aminophylline concentration may occur. Management: Lower the dose of aminophylline by 50% immediately after initiation of zileuton treatment. Use a lower starting dose if aminophylline is being added to an existing ziluton treatment. Monitoring for an increase in serum theophylline concentrations or effects. |
Risk Factor X (Avoid Combination) |
|
Acebrophylline | May intensify theophylline derivatives' stimulatory effects. |
Doxofylline | Doxofylline's toxic/adverse effects may be exacerbated by Theophylline Derivatives. |
Riociguat | Riociguat may have a hypotensive effect that can be amplified by Theophylline Derivatives. |
Monitoring Parameters:
Monitor theophylline levels 30 minutes after the initial loading dose and 24 hours of the maintenance dose or after dose adjustment. During therapy with theophylline, monitor:
- Heart rate
- CNS effects
- Respiratory rate
- arterial or capillary blood
How to administer aminophylline?
- The intravenous loading dosages need to be given during a 30-minute period.
- The infusion rate should not exceed 21 mg/hour for patients with cor pulmonale, decompensated heart disease, liver illness, individuals older than 60 years of age, or those taking specific drugs that affect aminophylline clearance.
- Avoid extravasation of the drug as it may cause serious skin-related adverse effects. If extravasation of theophylline into the skin occurs, follow these steps:
- stop the infusion,
- aspirate the fluid with the same IV line (DO NOT FLUSH THe LINE)
- administer hyaluronidase antidote (intradermal/ subQ 1 to 1.7 ml as five separate injections of 0.2 to 0.3 ml with a 25 gauge needle injected in a clockwise manner.
- Remove the needle,
- Apply cold compresses, and
- Elevate the limb.
Mechanism of action of Aminophylline:
- Bronchodilation is caused by the aminophylline and theophylline.
- It can also reduce the body's response to allergens through unknown mechanisms.
- It is used to prevent allergic airways disease.
- Theophylline increases calcium uptake via adenosine-mediated channel and also causes diaphragmatic muscle contraction to be increased.
It is bound to protein primarily albumin at 40% and is metabolized by the liver to active metabolites (caffeine, methylxanthine).
The half-life of a substance is variable. Half-life is affected by age, heart function, lung disease, smoking, and liver function.
- Premature infants, aged 3 to 15 days:
- 30 hours ranging from 17 to 43 hours
- Premature infants, postnatal age 25 to 57 days:
- 20 hours ranging from 9.4 to 30.6 hours
- Term infants (postnatal age 1-2 days):
- 25.7 hours ranging from 25 to 26.5 hours.
- Term infants postnatal age 3 to 30 weeks:
- 11 hours ranging from 6 to 29 hours
- Children 1 to 4 years:
- 3.4 hours ranging from 1.2 to 5.6 hours
- Children and Adolescents 6 to 17 years:
- 3.7 hours ranging from 1.5 to 5.9 hours
- Adults older than 18 years to less than 60 years of age:
- 8.7 hours ranging from 6.1 to 12.8 hours
- Elderly older than 60 years:
- 9.8 hours (range: 1.6 to 18 hours)
Time to reach the peak plasma concentration: 30 minutes
Excretion of Theophylline is via Urine ( 50% as unchanged drug). Smokers clear theophylline from the body twice as rapidly as non-smokers.
Aminophylline International Brand Names:
- Aminocont
- Aminofilina
- Aminomal
- Aminophyllin
- Aminophylline Renaudin
- Aminophyllinum
- Aminophyllinum Prolongatum
- Aminoslow
- Aminosol
- Amlin
- Asiphylline
- Asmafin
- Asmapen
- Asthcontin
- Brolin
- Cardiomin
- Cardirenal
- Cardophyllin
- Carine
- Clonofillin SR
- Diaphyllin
- Escophyllin
- Euphyllin Retard
- Filin
- Filotempo
- Lanrox
- Minoton
- Miofilin
- Neophyllin
- Pediatric Asthcontin for Children SR
- Peterphyllin
- Phaminov
- Pharmafil
- Phylin
- Phyllocontin
- Phyllotemp
- Retafilin
- Sofafyllin
- Syntophyllin
- Tefamin
- Teofyllamin Ipex
- Xing You Shan
Aminophylline Brand Names in Pakistan:
Aminophylline Injection 25 mg/ml in Pakistan |
|
AMINOPHYLLINE | LAHORE CHEMICAL & PHARMACEUTICAL WORKS (PVT) LTD |
AMPHILINE | ELITE PHARMA |
AMPHYLL | GLAXOSMITHKLINE |
Aminophylline Syrup 32 mg/5ml in Pakistan |
|
HYDILAR | ATLANTIC PHARMACEUTICALS (PVT) LTD. |
MASTER | MAX PHARMACEUTICALS |
Aminophylline Tablets 100 mg in Pakistan |
|
AMINOPHYLLINE | MIAN BROTHERS LABORATORIES (PVT) LTD. |
AMINOPHYLLINE | MUNAWAR PHARMA (PVT) LTD. |
AMINOPHYLLINE | UNEXO LABS (PVT) LTD. |
AMINOPHYLLINE | LISKO PAKISTAN (PVT) LTD |
AMPHYLL | GLAXOSMITHKLINE |
ASMOLIN | IRZA PHARMA (PVT) LTD. |
CONTOPHYLIN | REX PHARMACEUTICALS PAKISTAN |
CONTOPHYLIN | REX PHARMACEUTICALS PAKISTAN |
GEOPHYLLIN | GABA PHARMACEUTICALS LABS |
KOHILIN | KOHS PHARMACEUTICALS |
PHYLINE TABLET | REGENT LABORATORIES LTD. |
PHYLINE TABLET | REGENT LABORATORIES LTD. |
PHYLINE TABLET | REGENT LABORATORIES LTD. |
Aminophylline Tablets 225 mg in Pakistan |
|
PHYLLOCONTIN | AGP (PRIVATE) LTD. |